Search results
Results From The WOW.Com Content Network
Progressive familial intrahepatic cholestasis (PFIC) is a group of familial cholestatic conditions caused by defects in biliary epithelial transporters. The clinical presentation usually occurs first in childhood with progressive cholestasis. This usually leads to failure to thrive, cirrhosis, and the need for liver transplantation. [citation ...
Familial intrahepatic cholestasis (FIH) is a group of disorders that lead to intrahepatic cholestasis in children. [47] Most often, FIH occurs during the first year of life, with an incidence rate of 1/50,000 to 1/100,000. [48] There are three different versions of FIH, with each causing a different severity of jaundice.
Progressive familial intrahepatic cholestasis, a disease This page was last edited on 19 May 2023, at 21:31 (UTC). Text is available under the Creative Commons ...
This page was last edited on 26 September 2013, at 18:42 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Cholestasis facies are a type of facies considered a symptom of Alagille syndrome. [1] However it appears not to be specific but "a general feature of congenital intrahepatic cholestatic liver disease ".
The differential diagnosis can include primary biliary cholangitis (formerly referred to as primary biliary cirrhosis), drug-induced cholestasis, cholangiocarcinoma, IgG4-related disease, post-liver transplantation nonanastomotic biliary strictures, [23] and HIV-associated cholangiopathy. [24]
Feathery degeneration - large cells with pale flocculant cytoplasm (left-bottom and right-top).H&E stain.. In histo pathology, feathery degeneration, formally feathery degeneration of hepatocytes, is a form of liver parenchymal cell (i.e. hepatocyte) death associated with cholestasis.
Neonatal cholestasis refers to elevated levels of conjugated bilirubin identified in newborn infants within the first few months of life. [1] Conjugated hyperbilirubinemia is clinically defined as >20% of total serum bilirubin or conjugated bilirubin concentration greater than 1.0 mg/dL regardless of total serum bilirubin concentration. [ 2 ]